188813-02-7

Basic information

• Product Name: 3-BROMO-5-FLUOROBENZALDEHYDE
• Synonyms: 3-BROMO-5-FLUOROBENZALDEHYDE;3-Bromo-5-fluorobenzaldehyde 98%;3-FLUORO-5-BROMOBENZALDEHYDE;3-Bromo-5-fluorobenzaldehyde98%
• CAS NO: 188813-02-7
• Molecular Formula: C₇H₄BrFO
• Molecular Weight: 203.01
• Product Categories: Pyridine;Adehydes, Acetals & Ketones;Bromine Compounds;Fluorine Compounds;Fluorine series
• Mol File: 188813-02-7.mol

Chemical Properties

• Melting Point: 41-43℃
• Boiling Point: 230.985 °C at 760 mmHg
• Flash Point: 93.497 °C
• Appearance: /Solid
• Density: 1.43
• Vapor Pressure: 0.064mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: Room temperature.
• Water Solubility: Slightly soluble in water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: 3-BROMO-5-FLUOROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-FLUOROBENZALDEHYDE(188813-02-7)
• EPA Substance Registry System: 3-BROMO-5-FLUOROBENZALDEHYDE(188813-02-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 188813-02-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Bromo-5-fluorobenzaldehyde is used as an intermediate in organic syntheses for the production of various complex organic molecules. Its presence of both electron-withdrawing and electron-donating substituents on the benzene ring makes it a versatile building block for constructing a wide range of chemical compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Bromo-5-fluorobenzaldehyde is used as a reagent in the synthesis of 3,4-diamino-3-cyclobutene-1,2-diones. These compounds are of interest due to their potential applications as pharmaceutical agents, particularly in the development of new drugs with unique therapeutic properties.
Used in Material Science:
3-Bromo-5-fluorobenzaldehyde is also used as a reagent in the synthesis of 9,10-Dihydro-9,10-diboraanthracenes. These compounds are of interest in material science for their potential applications in the development of new materials with unique electronic, optical, or structural properties.

InChI:InChI=1/C7H4BrFO/c8-6-1-5(4-10)2-7(9)3-6/h1-4H

Upstream product

• 216755-56-5 5-fluoro-3-hydroxymethylbromobenzene 
• 1435-51-4 1,3-dibromo-5-fluorobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 627526-90-3 1-bromo-3-(difluoromethyl)-5-fluorobenzene 
• 1068-55-9 isopropylmagnesium chloride 

Downstream Products

• 627527-04-2 1-(3-bromo-5-fluorophenyl)ethanol 
• 304876-25-3 3-fluoro-5-bromobenzaldehyde oxime 
• 627526-90-3 1-bromo-3-(difluoromethyl)-5-fluorobenzene 
• 216755-56-5 5-fluoro-3-hydroxymethylbromobenzene 
• 1343455-54-8 4-{[1-(3-bromo-5-fluoro-phenyl)-methylidene]-amino}-benzoic acid ethyl ester 
• 1343455-52-6 N-[2-(4'-tert-butyl-5-fluoro-biphenyl-3-yl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl]-methanesulfonamide 
• 1343455-64-0 N-[2-(3-dimethylamino-5-fluoro-phenyl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl]-methanesulfonamide 
• 1343455-69-5 2-(4'-Cyano-5-fluoro-biphenyl-3-yl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid 
• 1343456-30-3 N-[2-(3-fluoro-5-pyrrolidin-1-yl-phenyl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl]-methanesulfonamide 
• 1343456-35-8 cyclopropanesulfonic acid [2-(3-fluoro-5-pyrrolidin-1-yl-phenyl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl]-amide 
• 1343456-67-6 cyclopropanesulfonic acid [2-(3-cyclohexyl-5-fluoro-phenyl)-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl]-amide 
• 1343456-90-5 N-{2-[3-Fluoro-5-(4-isopropyl-piperazin-1-yl)-phenyl]-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl}-methanesulfonamide 
• 1343456-95-0 2-[3-fluoro-5-(2-oxo-pyrrolidin-1-yl)-phenyl]-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid 
• 1343457-00-0 N-{2-[3-fluoro-5-(2-oxo-pyrrolidin-1-yl)-phenyl]-3,3-dimethyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl}-methanesulfonamide 

Relevant articles and documents

GLUCOSE SENSITIVE INSULIN DERIVATIVES

The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention

Method for synthesizing aromatic aldehyde through iron catalyzed oxidation allyl aromatic compound

The invention discloses a method for synthesizing aromatic aldehyde through an iron catalyzed oxidation allyl aromatic compound. According to the specific method, under the promotion effect of hydrogen silane, with air or oxygen as the oxidant, the aromatic aldehyde compound is synthesized through the iron catalyzed oxidation allyl aromatic compound, the reaction temperature is 20-150 DEG C, and the time is 0.25-60 h. The method has the advantages that a catalyst source is wide, the price is low and the environment is protected; an oxidant source is wide, the price is low and no waste is generated; the reaction conditions are mild, selectivity is high and the yield is high; a substrate source is wide and stable; a substrate functional group is high in compatibility and a substrate is widein application range; complicated small molecules are compatible and can be well converted into aldehyde. The target product separation yield can reach up to 96% under the optimized reaction conditions.

GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X-R2, and wherein "X" is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (lla) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1'-X'-R2', in which either the moeities R1' or R2' or X' carry a drug that is covalently attached to the diboron compound.

Synthesis and Transformations of Functionalized Benzosiloxaboroles

The synthesis and characterization of a series of fluorinated benzosiloxaboroles bearing synthetically useful formyl and cyano groups is reported. These compounds have been obtained by multistep syntheses starting with simple halogenated benzenes. The general synthetic protocol was based on the generation of ortho-boronated aryldimethylsilanes which undergo dehydrogenative cyclization upon hydrolytic workup due to activation of the Si–H bond by the adjacent boronic group. In some cases the synergy of adjacent boron- and silicon-based functionalities resulted in an unexpected hydrosilylation of the CHO group under mild aqueous conditions. The reduction of a benzosiloxaborole derivative bearing the formyl group at the ortho position with respect to the boron atom resulted in a structural transformation reflecting the higher stability of the carboxaborole heterocycle with respect to its silicon counterpart. Thus, a unique heterocyclic system featuring a central 10-membered ring comprising two borasiloxane linkages was isolated.

Benzocarbazoles dioxane derivatives, its preparation process and its use in medicine

The invention relates to a benzodioxane derivative, a preparation method thereof and application of the derivative in medicines. Specifically, the invention relates to a novel benzodioxane derivative shown as a formula (I), medial salt thereof or a medicine composition containing the derivative, and a preparation method of the derivative. The invention further relates to a use of the benzodioxane derivative and the medial salt thereof or the medicine composition containing the derivative in preparing therapeutic agent, especially GPR 40 agonist, and a drug for treating the diseases such as diabetes, metabolic disorders and the like, wherein each substituent group in the formula (I) is as defined in the description.

NOVEL CYTOCHROME P450 INHIBITORS AND THEIR METHOD OF USE

Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndro

HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES

The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

PROCESS FOR PREPARING TRIAZOLONES

The present process provides a improved method for the preparation of alkylsulfanyl substituted triazoles 2 which are useful intermediates in a new process for the preparation of triazolones

Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists

A series of 3,4- and 3,5-disubstituted phenyl-containing cyclobutenedione analogues were synthesized and evaluated as CXCR2 receptor antagonists. Variations in the disubstitution pattern of the phenyl ring afforded new compounds with potent CXCR2 binding

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1-R4 and Ar are as herein defined. Also disclosed in t